These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
410 related articles for article (PubMed ID: 12188412)
41. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Kumar AS; Benz CC; Shim V; Minami CA; Moore DH; Esserman LJ Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1028-33. PubMed ID: 18463402 [TBL] [Abstract][Full Text] [Related]
42. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Bird PA; Hill AG; Houssami N Ann Surg Oncol; 2008 Jul; 15(7):1983-8. PubMed ID: 18408976 [TBL] [Abstract][Full Text] [Related]
43. Histological category and expression of hormone receptors in ductal carcinoma in situ of the breast. Lebrecht A; Buchmann J; Hefler L; Lampe D; Koelbl H Anticancer Res; 2002; 22(3):1909-11. PubMed ID: 12168892 [TBL] [Abstract][Full Text] [Related]
45. [Expression of ER, PR and cyclin D1 in breast infiltrating ductal carcinoma and their clinicopathological significance]. Wang ZB; Zhao P; Liu M; Li XH Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(8):514-7. PubMed ID: 15949328 [TBL] [Abstract][Full Text] [Related]
46. Estrogen and progesterone hormone receptor status in breast carcinoma: comparison of immunocytochemistry and immunohistochemistry. Radhika K; Prayaga AK Indian J Cancer; 2010; 47(2):148-50. PubMed ID: 20448377 [TBL] [Abstract][Full Text] [Related]
47. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression. Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840 [TBL] [Abstract][Full Text] [Related]
48. Estrogen and progesterone receptor status in breast cancer: effect of oral contraceptive pills and hormone replacement therapy. Tewari M; Pradhan S; Singh U; Shukla HS Breast; 2007 Oct; 16(5):540-5. PubMed ID: 17587581 [TBL] [Abstract][Full Text] [Related]
49. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
50. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Di Saverio S; Gutierrez J; Avisar E Breast Cancer Res Treat; 2008 Oct; 111(3):541-7. PubMed ID: 18026874 [TBL] [Abstract][Full Text] [Related]
51. Preoperative profiling of symptomatic breast cancer by diagnostic core biopsy. Cahill RA; Walsh D; Landers RJ; Watson RG Ann Surg Oncol; 2006 Jan; 13(1):45-51. PubMed ID: 16378157 [TBL] [Abstract][Full Text] [Related]
52. [Immunohistochemical investigation of estrogen and progesterone receptors in breast tumors]. Ellinidi VN; Anikseeva NV; Goncharova OA; Krasnozhon DA; Fedorov KA Vopr Onkol; 2004; 50(2):234-6. PubMed ID: 15176229 [TBL] [Abstract][Full Text] [Related]
53. Ratio of concentrations of estrogen receptors to progesterone receptors (ER/PR) in the cytosol of breast cancers (stratification by forming of groups differing in PR). Hochmann J Neoplasma; 2007; 54(4):290-6. PubMed ID: 17822318 [TBL] [Abstract][Full Text] [Related]
54. [Receptor (ER, PgR) levels as prognostic factors in the endocrine therapy of pre- and post-menopausal patients with stage III infiltrative ductal and lobular cancer of the breast]. Calzada L; Salazar EL; Pedron Nuevo N Ginecol Obstet Mex; 1996 Mar; 64():135-9. PubMed ID: 8729191 [TBL] [Abstract][Full Text] [Related]
55. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome. Francis G; Beadle G; Thomas S; Mengersen K; Stein S Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275 [TBL] [Abstract][Full Text] [Related]
56. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477 [TBL] [Abstract][Full Text] [Related]
57. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554 [TBL] [Abstract][Full Text] [Related]
58. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer. Sutela A; Vanninen R; Sudah M; Berg M; Kiviniemi V; Rummukainen J; Kataja V; Kärjä V Acta Oncol; 2008; 47(1):38-46. PubMed ID: 17851859 [TBL] [Abstract][Full Text] [Related]
59. [Breast cancer: prognostic value of flow cytometry and hormone receptors. Apropos of a Lebanese series of patients]. Aftimos G; Trak-Smayra V; Moacdieh-Rehayel L J Med Liban; 2000; 48(1):8-17. PubMed ID: 10881437 [TBL] [Abstract][Full Text] [Related]
60. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]